TRACON Pharmaceuticals (NASDAQ:TCON) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research note issued on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Price Performance

TCON opened at $0.05 on Tuesday. TRACON Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $14.75. The stock’s 50 day moving average price is $0.09 and its 200 day moving average price is $0.69. The stock has a market cap of $154,814.00, a P/E ratio of 0.01 and a beta of 1.43.

TRACON Pharmaceuticals (NASDAQ:TCON) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) EPS for the quarter. The company had revenue of $0.06 million for the quarter.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.